S-EPMC11652503 - Assessment of clinical benefit, cost and uptake of biosimilars versus reference biologics in immune-mediated inflammatory diseases in China. - OmicsDI

Unknown

Dataset Information

Assessment of clinical benefit, cost and uptake of biosimilars versus reference biologics in immune-mediated inflammatory diseases in China.

ABSTRACT:

SUBMITTER: Du X

PROVIDER: S-EPMC11652503 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature